Clinical trial NCT04704713: Afamelanotide in Patients Suffering From Polymorphic Light Eruption (PLE)
Official title: A Phase III, Randomised, Double Blind, Placebo Controlled, Parallel Group Study, to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide (16 mg) in Patients Suffering From Polymorphic Light Eruption (PLE)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Polymorphic Light Eruption
Lead sponsor: Clinuvel Pharmaceuticals Limited
Sponsor class: INDUSTRY
First posted: 2021-01-12
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study was to evaluate the safety and efficacy of afamelanotide in patients suffering from polymorphic light eruption (PLE).


Eligibility criteria: Inclusion Criteria:

* Aged greater than 18 years
* Male or female patients with a documented history of PLE diagnosed or confirmed by a photodermatologist or photobiologist, with a history of PLE related pruritus symptoms.
* Recurrent PLE episodes that occur at least once a year (as evidenced by PLE related pruritus symptoms) developing in their own country (to exclude patients affected only when traveling to sunnier climates)
* Written informed consent prior to the performance of any study-specific procedure
* Are willing and able to comply with the conditions specified in the protocol and study procedures in the opinion of the Investigator

Exclusion Criteria:

* Currently requiring treatment with systemic immunosuppressive agents
* Documented history of other photosensitivity conditions which may be confused with PLE or interfere with the assessment of PLE episodes
* Solarium use in the three months prior to study involvement and throughout the duration of the study
* Use of immunosuppressive medications, drugs that cause hyperpigmentation or any other treatment that in the opinion of the Investigator may interfere with this study
* Documented presence (\> 1 in 320) of Anti-Nuclear Antibody (ANA) and/or positive Extractable Nuclear Antibody (ENA); historical results from the 3 years prior to randomisation are acceptable if available
* In the opinion of the Investigator, any evidence of clinically significant organ dysfunction, or any clinically significant deviation from normal in clinical or laboratory parameters
* History of drug or alcohol abuse (in the last 1 year)
* Female who is pregnant (confirmed by positive serum beta-Human chorionic gonadotropin (β-HCG) pregnancy test prior to baseline) or lactating
* Female of child-bearing potential (pre-menopausal, not surgically sterile) that is not using or is not willing to use adequate contraceptive measures (e.g. oral contraceptives, condoms, diaphragm plus spermicide, intrauterine device)
* Sexually active men with partners of child bearing potential not willing to use barrier contraception during the trial and for a period of three months thereafter
* Participation in a clinical trial with another Investigational Medicinal Product (IMP) within 30 days prior to the Screening visit or during the study
* Hypersensitivity to afamelanotide or any of its components

Primary outcomes:
measure: Severity of PLE Related Pruritus Recorded Using an 11-point Likert Scale
timeFrame: From Day 0 to Day 120
Secondary outcomes:
measure: Frequency (Number) of Documented PLE Episodes Recorded in Paper Patient Diaries
timeFrame: From Day 0 to Day 120
measure: Duration of PLE Episodes Recorded in Paper Patient Diaries
timeFrame: From Day 0 to Day 120
measure: Quality of Life Using the Dermatology Life Quality Index (DLQI)
timeFrame: At Day 0, Day 60 and Day 120
Other outcomes:
Locations:
Study officials:
References: